Ontology highlight
ABSTRACT: Background
Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r)?±?dasabuvir (DSV)?±?ribavirin (RBV) for treatment in HCV/HIV coinfected patients.Methods
We systematically searched and included studies that enrolled patients with HIV/HCV coinfection using the OBV/PTV/r?±?DSV?±?RBV regimens and reported sustained virological response after 12?weeks (SVR12) end-of-treatment. Heterogeneity of results was assessed and pooled SVR rates were computed with 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger's test were further performed.Results
Ten studies containing 1358 coinfected patients were included in this study. The pooled estimate of SVR12 was 96.3% (95%CI: 95.1-97.4). Subgroup analysis showed that pooled SVR12 rate was 96.2% (95% CI: 94.8-97.4) for patients with genotype (GT) 1 and 98.8% (95% CI: 95.1-100.0) for those with GT4. The SVR12 rates for the treatment-naïve (TN) and treatment-experienced (TE) patients were 96.8% (95% CI, 94.8-98.5) and 98.9% (95% CI, 96.4-100.0), respectively. Pooled SVR12 rate was 97.8(95%CI: 94.6-99.8) for patients with cirrhosis and 96.7% (95%CI: 95.3-97.8) without cirrhosis. The pooled incidence of any adverse events (AEs) and serious adverse events (SAEs) was 73.9% (95%CI: 38.1-97.6) and 2.7% (95%CI: 0.0-9.5). Publication bias did not exist in this study.Conclusions
The comprehensive analysis showed high efficacy for the OBV/PTV/r?±?DSV?±?RBV regimen in patients coinfected with HIV and HCV, regardless of genotypes, history of treatment and the presence or absence of cirrhosis.
SUBMITTER: Wu J
PROVIDER: S-EPMC6337763 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
Wu Jingjing J Huang Peng P Fan Haozhi H Tian Ting T Xia Xueshan X Fu Zuqiang Z Wang Yan Y Ye Xiangyu X Yue Ming M Zhang Yun Y
Virology journal 20190117 1
<h4>Background</h4>Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r) ± dasabuvir (DSV) ± ribavirin (RBV) for treatment in HCV/HIV coinfected patients.<h4>Methods</h4>We systematically searched and included studies that enrolled patients with HIV/HCV coinfection using the OBV/PTV/r ± DSV ± RBV re ...[more]